LifeSci Capital analyst Oliver McCammon has maintained their bullish stance on CADL stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oliver McCammon has given his Buy rating due to a combination of factors tied to Candel Therapeutics’ lead asset, CAN-2409, and its clinical trajectory. He emphasizes that the product has already shown a meaningful reduction in disease recurrence when added to standard radiation and short-course ADT in localized prostate cancer, and that the company is proceeding toward a planned BLA filing targeted for Q4 2026, which frames a clear regulatory and commercialization pathway.
McCammon also highlights the upcoming extended follow-up data, including prostate cancer–specific disease-free survival, time to salvage therapy, and time to metastasis, which are expected to further reinforce the clinical profile and support regulatory success. In addition, the planned plenary presentation at the AUA 2026 meeting should increase visibility of CAN-2409 among clinicians and investors, while Candel’s multi‑year cash runway provides a financial buffer to execute on its development plans without near‑term financing pressure.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $23.00 price target.